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Abstract Complex formation processes of rhodium(III)-η5-pentamethylcyclopentadienyl 
cation [RhCp*(H2O)3]
2+ with 1,2-dimethyl-3-hydroxy-pyridin-4(1H)-one (deferiprone, dhp) 
and pyridine-2-carboxylic acid (pic) were studied with the aid of pH-potentiometry, 1H NMR 
and UV-visible spectrophotometry in aqueous solution in the presence and in the absence of 
chloride ions. Stoichiometry and overall stability constants of the complexes formed were 
determined. Formation of mononuclear, mono-ligand complexes such as [RhCp*(L)Z] (where 
L = dhp or pic; Z = Cl‒ or H2O) and mixed-hydroxido species [RhCp*(L)(OH)] was found. 
Relatively high pKa values (9.32‒11.90) were determined for the hydrolysis of the 
[RhCp*(L)Z] complexes. [RhCp*(L)Z] species predominate at physiological pH, and 
negligible decomposition is probable only at low micromolar concentrations. More favored 
complex formation was found in the case of pic. Stability of the studied organorhodium 
complexes was compared to analogous Ru(II)(h6-p-cymene) compounds. In addition, the 
aqua/chlorido ligand replacement reaction in the complexes [RhCp*(L)(H2O)]
+ of dhp and pic 
was monitored to provide equilibrium constants with which the extent of aquation at various 
chloride concentrations can be estimated. Single crystals of [RhCp*(dhp)Cl] suitable for X-
ray diffraction analysis were also obtained. The [RhCp*(L)Cl] complexes of dhp and pic were 
tested for cytotoxicity in various human cancer cell lines where they showed activity 
depending on the attached ligand scaffold. 
3 
1. Introduction 
 
The research area of metal-based anticancer drugs was mainly fueled by the 
groundbreaking development of cisplatin (cis-diamminedichloridoplatinum(II)), one of the 
leading agents in clinical use. Despite the importance and pharmacological activity of Pt 
drugs, especially in combination therapy, there are exciting efforts to develop novel types of 
antitumor agents seeking to overcome intrinsic and acquired resistance phenomena and side 
effects of these Pt containing drugs [1-3]. The novel drug candidates need to exhibit improved 
efficacy and selectivity as well as more tolerable side effects as compared to established 
chemotherapeutics. Complexes of the neighboring transition metals such as Ru, Os, Ir and Rh 
are an attractive alternative field of drug development beside the platinum area. Ru(III)-based 
complexes such as trans-[tetrachlorido(1H-imidazole)(dimethylsulfoxide-κS)ruthenate(III)] 
(NAMI-A) [4] and indazolium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] (KP1019) 
[5] are the best studied representatives, and the sodium analogue KP1339 [6] of the latter is 
currently investigated in clinical trials. Organometallic “piano stool” h-arene (such as p-
cymene, biphenyl, tetrahydroanthracene) or h-cyclopentadienyl water-soluble complexes of 
Ru and Os are extensively investigated, and some of them are active against tumor cells 
which have become resistant to cisplatin [7,8]. However, relatively few studies are focused on 
related Rh(II/III) compounds with antitumor activity [9-11]. The anticancer properties of 
RhCl3 and its simple complexes such as mer-[RhCl3(NH3)3] were already reported some 
decades ago [12,13]. Effective inhibition of the viability of human cancer cells was found in 
the case of various dirhodium(II,II) carboxylate complexes [14,15]. Promising 
antiproliferative activities measured in human cancer cell lines have been reported for half-
sandwich Rh complexes of bidentate polypyridyl ligands by Sheldrick et al. [16-18]. 
In the half-sandwich complexes of Rh(III) the ligand exchange processes are 
considerably faster compared to the hexaaqua complex, especially when anionic ligands (such 
as pentamethylcyclopentadienyl) are coordinated [9]. Additionally, the type of the co-
ligand(s) has strong effect on physical-chemical and biological properties of the 
organometallic complex such as the solution stability and the hydro-lipophilic character, 
which can influence cellular uptake, pharmacokinetics and biological activity. Knowledge of 
the thermodynamics and kinetics of aquation (or designated as hydrolysis, i.e. replacement of 
the leaving group by a water molecule), ligand substitution (i.e. replacement of the co-ligand 
by water molecules or endogenous compounds) is a mandatory prerequisite for understanding 
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the transformation processes of the metallodrugs in the aqueous phase under physiological 
conditions and their mechanism of action [8,19]. 
Recently, we reported Rh(III)-η5-pentamethylcyclopentadienyl (RhCp*) complexes 
bearing 3-hydroxyflavone and 3-hydroxy-4-pyrone ligands [20,21]. These 3-hydroxyflavone 
complexes have very limited water solubility, and their cytotoxicity could not be tested [20]. 
Complexes of 3-hydroxy-2-methyl-pyran-4(1H)-one (maltol) and 5-hydroxy-2-methyl-pyran-
4(1H)-one (allomaltol) with much better solubility were tested in the human cancer cell lines 
CH1, SW480 and A549 and were found to exhibit minor cytotoxicity with IC50 values of 
~100–300 μM [21]. Detailed solution equilibrium studies of RhCp* complexes formed with 
various ligands are fairly rare in the literature [22-24], especially which provide stability 
constants. Our previous work on RhCp* complexes of maltol and allomaltol revealed the 
formation of mono-ligand species which predominate at physiological pH and can decompose 
partially at micromolar concentrations on the basis of the determined stability constants [21]. 
In this work our aim was to investigate the effect of the exchange of the (O,O) donor 
hydroxypyrone ligands for a hydroxypyridinone or an (N,O) donor (picolinate) on the stability 
and the biological activity. For these studies, the well-known hydroxypyridinone, 1,2-
dimethyl-3-hydroxy-pyridin-4(1H)-one (deferiprone, dhp) and pyridine-2-carboxylic acid 
(picolinic acid, pic) (see chart 1) were chosen. Analogous Ru(II)(h6-p-cymene) and Os(II)(h6-
p-cymene) complexes of pic have been reported to show moderate antiproliferative activity 
[8,25], although the IrCp* complex of pic represents quite low efficacy [26].  
Chart 1 
Here we report the solution equilibria of RhCp* complexes of dhp and pic studied by 
pH-potentiometry, 1H NMR spectroscopy and UV-visible (UV-Vis) spectrophotometry. The 
chlorido/aqua co-ligand exchange processes in the complex [RhCp*(L)Cl] (where L = dhp or 
pic) of the chosen ligands was also monitored. Stability constants of the complexes were 
determined in the presence and in the absence of the competitive chloride ions. Additionally, 
the [RhCp*(L)Cl] complexes of dhp and pic were synthesized (see chart 2), and their 
biological activity was investigated in human cancer cells.   
Chart 2 
 
2. Experimental section 
 
2.1. Chemicals 
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All solvents were of analytical grade and used without further purification. Dhp, pic, 
sodium methoxide, KCl, KNO3, AgNO3, HCl, HNO3 and KOH were purchased from Sigma-
Aldrich and used without further purification. Dimeric rhodium precursor [RhCp*(m-Cl)Cl]2 
and chlorido[1,2-dimethyl-3-(oxo-κO)-pyridin-4(1H)-onato-κO](η5-1,2,3,4,5-
pentamethylcyclopentadienyl)rhodium(III) (1) and chlorido[2-pyridine-2-carboxylato](η5-
1,2,3,4,5-pentamethylcyclopentadienyl)rhodium(III)  (2) were prepared according to literature 
procedures [27,28]. Elemental analyses were carried out with a Perkin Elmer 2400 CHN 
Elemental Analyzer by the Microanalytical Laboratory of the University of Vienna. NMR 
spectra were recorded at 25 °C using a Bruker FT-NMR spectrometer Avance IIITM 500 MHz. 
1H-NMR spectra were measured at 500.10 MHz and 13C{1H}-NMR spectra at 125.75 MHz in 
d4-MeOH. The 2D NMR spectra were measured in a gradient-enhanced mode. The exact 
concentration of the ligand stock solutions together with the proton dissociation constants 
were determined by pH-potentiometric titrations with the help of the computer program 
HYPERQUAD [29]. A stock solution of [RhCp*Z3] (where Z = H2O and/or Cl
−; charges are 
omitted for simplicity) was obtained by dissolving a known amount of [RhCp*(m-Cl)Cl]2 in 
water, while the stock solution of [RhCp*(H2O)3](NO3)2 was obtained from an aqueous 
solution of [RhCp*(m-Cl)Cl]2 after removal of chloride ions using equivalent amounts of 
AgNO3. The exact concentrations of the RhCp* stock solutions (with or without chloride) 
were checked by pH-potentiometric titrations employing our previously published stability 
constants for [(RhCp*)2(hydroxido)i] (i = 2 or 3) complexes [21].  
  
2.2. pH-Potentiometric measurements 
 
The pH-potentiometric measurements for determination of the proton dissociation 
constants of the ligands and the overall stability constants of the RhCp* complexes were 
carried out at 25.0 ± 0.1 °C in water and at an ionic strength of 0.20 M KCl or KNO3 used for 
keeping the activity coefficients constant. The titrations were performed with carbonate-free 
KOH solution (0.20 M). The exact concentrations of HCl, HNO3 and KOH solutions were 
determined by pH-potentiometric titrations. An Orion 710A pH-meter equipped with a 
Metrohm combined electrode (type 6.0234.100) and a Metrohm 665 Dosimat burette were 
used for the pH-potentiometric measurements. The electrode system was calibrated to the pH 
= −log[H+] scale by means of blank titrations (strong acid vs. strong base: HCl or HNO3 vs. 
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KOH), as suggested by Irving et al. [30]. The average water ionization constant, pKw, was 
determined as 13.76 ± 0.01 at 25.0 °C, I = 0.20 M (KCl, KNO3), which corresponds well to 
the literature [31]. The reproducibility of the titration points included in the calculations was 
within 0.005 pH units. The pH-potentiometric titrations were performed in the pH range 
2.0−11.5. The initial volume of the samples was 10.0 mL. The ligand concentration was 
1.0−2.0 mM and metal ion-to-ligand ratios of 1:1 to 1:4 were used. The accepted fitting of the 
titration curves was always less than 10 mL. Samples were degassed by bubbling purified 
argon through them for ca. 10 min prior to the measurements and it was also passed over the 
solutions during the titrations. 
  The computer program PSEQUAD [32] was utilized to establish the stoichiometry of 
the complexes and to calculate the overall stability constants. MpLqHr is defined for the 
general equilibrium (1): 
pM + qL + rH  MpLqHr as (MpLqHr) = [MpLqHr]/[M]
p[L]q[H]r  (1) 
where M denotes the metal moiety RhCp* and L the completely deprotonated ligand. 
Literature log values of the various RhCp* - hydroxido complexes formed in the absence 
and presence of chloride ions were used [21] and compared to data collected in the course of 
the experiments described herein. In all calculations exclusively titration data were used from 
experiments in which no precipitate was visible in the reaction mixture. 
 
2.3. UV–Vis spectrophotometric and 1H NMR measurements 
 
A Hewlett Packard 8452A diode array spectrophotometer was used to record the UV-
Vis spectra in the interval 200–800 nm. The path length was 1 cm. UV–Vis measurements for 
[RhCp*Z3] – pic system were carried out at 1:1 metal-to-ligand ratio by preparing individual 
samples in which KCl or KNO3 was partially or completely replaced by HCl or HNO3 and pH 
values, varying in the range ca. 0.7–2.0, were calculated from the strong acid content. The 
H2O/Cl
− exchange processes in the complexes [RhCp*(L)(H2O)]  (where L = dhp or pic) were 
followed spectrophotomerically (ccomplex = 270 mM) at pH 7.40 (L = dhp) or at pH 3.50 (L = 
pic) while the Cl− concentration was varied between 0 and 1.0 M. Stability constants of the 
complexes [RhCp*(pic)Z]  and logK’ for the H2O/Cl
− exchange process were calculated with 
the computer program PSEQUAD [32]. 
1H NMR titrations were carried out on a Bruker Ultrashield 500 Plus instrument. All 
spectra were recorded with the WATERGATE water suppression pulse scheme using 4,4-
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dimethyl-4-silapentane-1-sulfonic acid as an internal NMR standard. The ligands were 
dissolved in a 10% (v/v) D2O/H2O mixture to yield a concentration of 1 mM and were titrated 
at 25 °C, at I = 0.20 M (KCl or KNO3) in absence or presence of [RhCp*Z3] at 1:1 metal-to-
ligand ratio.  
 
2.4. Synthesis of RhCp* complexes of dhp and pic 
 
Chlorido[1,2-dimethyl-3-(oxo-κO)-pyridin-4(1H)-onato-κO](η5-1,2,3,4,5-
pentamethylcyclopentadienyl)rhodium(III) 1 
Standard procedure: dhp (100 mg, 0.72 mmol, 1 eq) and sodium methoxide (43 mg, 
0.79 mmol, 1.1 eq) were dissolved in dry methanol (20 mL) and [RhCp*(m-Cl)Cl]2 (200 mg, 
0.32 mmol, 0.9 eq) was added in one portion. The obtained deep red solution was stirred for 
26 h at room temperature. The solvent was removed under reduced pressure; the residue was 
dissolved in CH2Cl2, filtered, concentrated and precipitated with diethyl ether. The red 
product was separated by filtration and dried in vacuo (153 mg, 57%). The isolated yield was 
found to be lower compared to the literature data (90%) [28]. 1H NMR (500.10 MHz, CDCl3): 
δ = 1.72 (s, 15H, -CH3,Cp*), 2.40 (s, 3H, 2-CH3,Pyr), 3.59 (s, 3H, N-CH3), 6.34 (d, 
3J(H,H) = 7 
Hz, 1H, H5), 6.90 (d, 3J(H,H) = 7 Hz, 1H, H6); 13C NMR (125.75 MHz, CDCl3): δ = 8.8 (-
CH3,Cp*), 12.3 (-CH3,C1), 40.3 (N-CH3), 90.6 (CCp*), 109.7 (C5), 131.6 (C6), 132.3 (C2), 161.3 
(C3), 175.6 (C4); Elemental analysis calcd (%) for C17H23ClNO2Rh*0.75H2O: C 48.02, H 
5.81, N 3.29; found: C 48.04, H 5.74, N 3.22. 
 
Chlorido[2-pyridine-2-carboxylato](η5-1,2,3,4,5-pentamethylcyclopentadienyl)rhodium(III) 2 
Standard procedure: pic (91 mg, 0.72 mmol, 1 eq) and sodium methoxide (43 mg, 
0.79 mmol, 1.1 eq) were dissolved in dry methanol (20 mL) and [RhCp*(m-Cl)Cl]2 (200 mg, 
0.32 mmol, 0.9 eq) was added in one portion. The obtained orange solution was stirred for 
18 h at room temperature. The solvent was removed under reduced pressure; the residue was 
dissolved in CH2Cl2, filtered, concentrated and precipitated with diethyl ether. The orange 
product was separated by filtration and dried in vacuo (180 mg, 70%). The yield was found to 
be lower compared to the literature data (81%) [28]. 1H NMR (500.10 MHz, CDCl3): δ = 1.77 
(s, 15H, -CH3,Cp*), 7.58–7.65 (m, 1H, H5), 7.97–8.00 (m, 1H, H4), 8.16 (d, 
3J(H,H) = 8 Hz, 
1H, H3), 8.60 (d, 3J(H,H) = 5 Hz, 1H, H6); 13C NMR (125.75 MHz, CDCl3): δ = 9.0 (-
CH3,Cp*), 93.9 (CCp*), 127.2 (C3), 128.0 (C5), 139.3 (C4), 149.0 (C2), 153.0 (C6), 170.0 
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(COO-); Elemental analysis calcd (%) for C16H19ClO2NRh*0.5H2O: C 47.49, H 4.98, N 3.46; 
found: C 47.74, H 4.94, N 3.41. 
 
2.5. Crystallographic structure determination 
 
Single crystals of 1 were obtained by using the slow diffusion method from CHCl3/n-
hexane and analyzed on a Bruker D8 Venture diffractometer at 100 K. The single crystal was 
positioned at 35 mm from the detector and 2243 frames for 6.4 s exposure time over 0.4° scan 
width were measured. The data were processed using the SAINT software package [33]. The 
structures were solved by direct methods and refined by full-matrix least-squares techniques. 
Non-hydrogen atoms were refined with anisotropic displacement parameters. Hydrogen atoms 
were inserted at calculated positions and refined with a riding model. The following computer 
programs were used: structure solution, SHELXS-97 [34]; refinement, SHELXL-2013 [34]; 
OLEX2 [35]; SHELXLE [36]; molecular diagrams, ORTEP-3 [37]; scattering factors [38]. 
The crystallographic data files for 1 have been deposited with the Cambridge Crystallographic 
Database as CCDC 1024661. 
 
2.6. Cell lines and culture conditions, cytotoxicity tests in cancer cell lines 
 
Cell lines and culture conditions: CH1 cells originate from an ascites sample of a 
patient with an adenocarcinoma of the ovary and were a gift from Lloyd R. Kelland, CRC 
Centre for Cancer Therapeutics, Institute of Cancer Research, Sutton, UK. SW480 (human 
adenocarcinoma of the colon) and A549 (human non-small cell lung cancer) cells were 
provided by Brigitte Marian (Institute of Cancer Research, Department of Medicine I, 
Medical University of Vienna, Austria). All cell culture reagents were obtained from Sigma-
Aldrich and plastic ware from Starlab (Germany). Cells were grown in 75 cm² culture flasks 
as adherent monolayer cultures in Minimum Essential Medium (MEM) supplemented with 
10% heat-inactivated fetal calf serum, 1 mM sodium pyruvate, 4 mM L-glutamine and 1% 
non-essential amino acids (from 100× ready-to-use stock). Cultures were maintained at 37 °C 
in humidified atmosphere containing 95% air and 5% CO2. 
 
MTT assay: Cytotoxicity was determined by the colorimetric MTT [3-(4,5-dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide] microculture assay. For this purpose, cells 
were harvested from culture flasks by trypsinisation and seeded in 100 μL/well aliquots into 
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96-well microculture plates. Cell densities of 1.0 × 103 cells/well (CH1), 2.0 × 103 cells/well 
(SW480) and 3.0 × 103 cells/well (A549) were chosen in order to ensure exponential growth 
of untreated controls throughout the experiment. Cells were allowed to settle and resume 
exponential growth in drug-free complete culture medium for 24 h. Stock solutions of the test 
compounds in dimethyl sulfoxide (DMSO) were diluted in complete culture medium and 
added to the plates (100 µL/well) where the maximum DMSO content did not exceed 0.5%. 
After 96 h of exposure, all media were replaced with 100 μL/well of MTT/RPMI1640 mixture 
(six parts of RPMI1640 medium supplemented with 10% heat-inactivated fetal bovine serum 
and 4 mM L-glutamine; one part of 5 mg/mL MTT reagent in phosphate-buffered saline). 
After incubation for 4 h, the supernatants were removed and the formazan crystals formed by 
viable cells were dissolved in 150 μL DMSO per well. Optical densities at 550 nm were 
measured with a microplate reader (BioTek ELx808) by using a reference wavelength of 690 
nm to correct for unspecific absorption. The quantity of viable cells was expressed as 
percentage of untreated controls, and 50% inhibitory concentrations (IC50) were calculated 
from concentration-effect curves by interpolation. Evaluation is based on means from three 
independent experiments, each comprising three replicates per concentration level. 
 
3. Results and discussion 
3.1. Synthesis of organometallic Rh(III) complexes and characterization 
 
The Rh precursor [RhCp*(m-Cl)Cl]2 was synthesized according to literature procedures 
by reaction of RhCl3 with pentamethylcyclopentadiene [27]. The RhCp* complexes of dhp 
and pic (see chart 2) were obtained according to the procedure described by Abbott et al. [28]. 
The ligands were deprotonated by sodium methoxide, followed by conversion with the Rh(III) 
dimer at room temperature, and pure compounds were isolated after work up. The isolated 
yields were found to be 57% and 70% for the complexes of dhp and pic, respectively. The 
organometallic Rh(III) complexes were characterized by NMR spectroscopy (1H, 13C) and 
elemental analysis. The recorded 1H NMR spectra confirmed the coordination of the anionic 
ligand scaffolds to the organorhodium fragments. The α-proton next to the carbonyl group of 
the pyrone ring was shifted to higher fields upon coordination of the metal ion, whereas the 
signal assigned to the β-proton of the backbone was found slightly low-field shifted compared 
to the free ligands (see figures S1 and S2), which is comparable to the analogous Ru(II) 
complexes [39]. The dhp organometallic was found to possess a remarkable high solubility in 
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PBS (> 100 mM) in contrast to the pic derivative (~1 mM in 1% DMSO/PBS), and both 
complexes were sufficient stable in aqueous solution to perform biological experiments. 
Single crystals of 1 were obtained by the slow diffusion method from CHCl3/n-hexane 
and the result of the X-ray diffraction study is shown in figure 1. Crystal data, data collection 
parameters, and structure refinement details are given in table 1. Complex 1 crystallized in the 
monoclinic space group P21/n. The Rh(III) center exhibits a pseudo-octahedral geometry 
(“piano-stool”), and the Cp* moiety occupies facially three coordination sites, while the 
deprotonated dhp ligand binds in a bidentate manner via its (O,O) donor atoms (Rh–O1: 
2.1318(11) Å, Rh–O2: 2.0726(10) Å) and the coordination sphere is completed with a 
chlorido ligand (Rh–Cl: 2.4361(4) Å). In addition, three molecules of chloroform per complex 
co-crystallized in the elemental unit, and each of them was found in close proximity to the 
hetero atoms around the Rh(III) center, with short contacts of the CHCl3 hydrogen to the 
respective donor atom (2.1–2.5 Å). The coordination sphere leads to a chiral center at the 
rhodium atom and both enantiomers were found in the unit cell. The measured bond length 
and angles between the metal center and the donor atoms were found in the same range as 
reported for related structures [28]. 
Figure 1 
Table 1 
 
3.2. Proton dissociation processes of the ligands and hydrolysis of [RhCp*(H2O)3]
2+  
 
Proton dissociation equilibria of the studied ligands dhp and pic are well known in the 
literature [40-42], and pKa values determined by pH-potentiometry (see table 2) are in 
reasonably good agreement with data reported under identical conditions as used in this study 
[43,44] with the exception of dhp (at I = 0.20 M (KNO3)) where no data were available.  
Table 2  
According to literature data the aqua complex [RhCp*(H2O)3]
2+ has a 
pseudooctahedral piano-stool type geometry, while its major hydrolysis product is a m-
hydroxido-bridged dinuclear species, [(RhCp*)2(μ-OH)3]
+ [22,45]. Both structures were 
proved by X-ray crystallography [22,45]. Recently, we have reported the hydrolytic behavior 
of the species [RhCp*(H2O)3]
2+ at various ionic strengths such as 0.20 M KNO3 and 0.20 M 
KCl [21]. The stoichiometry and overall stability constants of the dimer hydroxido complexes 
[(RhCp*)2(μ-OH)3]
+ and [(RhCp*)2(μ-OH)2Z2] (Z = H2O or Cl
−, charges are omitted) were 
determined by pH-potentiometric and 1H NMR titrations (see table 2), and these data were 
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used in this work for the calculations. The equilibrium states can be always reached quite fast 
in the pH range 2−11.5 in both media. It was also found that the chloride ions suppress the 
hydrolysis and shift the formation of the hydroxide-bridged dimers to the higher pH range, 
thus hydrolysis starts at pH > ~5 and pH > ~6 in the absence and in the presence of chloride 
ions, respectively [21]. It is noteworthy that the tendency of [RhCp*Z3]
 to hydrolyze is 
undoubtedly weaker compared to the isoelectric species [Ru(II)(h6-p-cymene)Z3]
 [46]. 
 
3.3. Complex formation of [RhCp*Z3] with dhp and pic in chloride-free and chloride-
containing media 
 
Solution equilibrium processes in the [RhCp*Z3] ‒ dhp and pic systems were 
investigated in aqueous solutions by the combined use of pH-potentiometric and 1H NMR 
titrations in the absence and presence of 0.20 M chloride ions. The complex formation takes 
place quickly, the equilibrium states establish in both media within 10 minutes in the pH 
range studied (2-11.5). The stoichiometries and overall stability constants of the metal 
complexes furnishing the best fits to the experimental titration data are listed in table 2. 
Formation of only mono-ligand complexes such as [ML] (as [RhCp*(L)Z] (charges are 
omitted) and [MLH‒1] (as [RhCp*(L)H‒1] = [RhCp*(L)(OH)], vide infra) was detected. 
According to the pH-potentiometric titration curves the complex formation with dhp 
starts already at pH ~2 in the chloride-free medium, while only at pH > 3.7 in the presence of 
chloride ions. This is in good agreement with the pH-dependent 1H NMR data (see 
representative spectra in figure 2 in the presence of chloride ions). Since slow ligand-
exchange processes can be observed in the 1H NMR spectra of the [RhCp*Z3] – dhp system 
with respect to the NMR time scale (t1/2(obs) > ~1 ms), peaks belonging to the protons of the 
free or bound ligand and to the bound or non-bound Cp* moiety can be detected separately. 
Formation of complex [RhCp*(L)Z] can be clearly seen in the acidic pH range, which 
predominates between pH 6.5 and 9. Additionally, two parallel processes take place at pH > 
9.5: i) The upfield shift of the peaks belonging to [RhCp*(L)Z] indicates the formation of the 
hydrolysis product [RhCp*(L)(OH)]; their signals are not separated since species with the 
same metal-to-ligand ratio in different protonation states represent usually fast exchange 
processes. ii) Signals assigned to free ligand and to the non-bound metal moiety appear in the 
spectra owing to the partial decomposition of mono-ligand complex. The integrated peak 
areas of the methyl protons of Cp* were converted to molar fractions and plotted together 
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with the concentration distribution curves (see figure 3) calculated on the basis of the stability 
constants obtained by pH-potentiometry. Fairly good correlations between the data of both 
methods were observed. Quite similar speciation was found in the chloride-free medium (in 
table 2), although the overall stability constants of the mono-ligand complexes are higher and 
pK of [RhCp*(L)Z] is significantly lower compared to those obtained in the presence of 
chloride ions. This difference can be explained by the fact that chloride ions acting as 
competitive ligands can suppress the formation of the complexes. It is noteworthy that a 
similar tendency was reported for RhCp* complexes of maltol, allomaltol and for Ru(II)(h6-p-
cymene) complexes formed with various ligands [21,44,47].   
Figures 2 and 3 
In the species [RhCp*(dhp)Z] the ligand coordinates  via the anionic bidentate (O,O)-
donor set as it was shown for complex 1 (see figure 1) by X-ray crystallography. Notably, X-
ray crystal structures of analogous Ru(II)(h6-p-cymene) and Os(II)(h6-p-cymene) complexes 
of dhp reveal quite similar geometry [48]. On the other hand the species of the general 
formula [RhCp*(L)H‒1] are considered as mixed hydroxido [RhCp*(L)(OH)] species formed 
by deprotonation of the coordinated water molecule or (partly) by the replacement of the 
chlorido ligand in chloride-containing medium. 
1H NMR spectra recorded for the [RhCp*Z3] – pic system depicted in figure 4 and the 
pH-potentiometric titration curves indicate that the complex formation takes place already in 
the strongly acidic pH range in both media. (The fractions of the free ligand and metal ion are 
fairly low at pH ~2). Thus the stability constants of species [RhCp*(pic)Z] were determined 
by deconvolution of the UV–Vis spectra measured between pH 0.7 and 2.0 (in table 2). These 
spectra were recorded for individual samples in which the KCl (or KNO3) was partially or 
completely replaced by HCl (or HNO3) and the actual pH values were calculated based on the 
strong acid content, while the changes of the metal-to-ligand charge-transfer and ligand bands 
were followed. The complex [RhCp*(pic)Z] predominates in a wide pH range including 
physiological pH as the concentration distribution curves show in figure 5a. In order to 
represent the significantly high stability of this complex molar fraction was computed as a 
function of total concentrations at pH 7.4 (see figure 5.b). Negligible decomposition of 
species [RhCp*(pic)Z] can be predicted even in the low-micromolar concentration range in 
both studied media. In this complex coordination through (N,O) donor atoms of picolinate 
was reported by Abbott et al. [28]. The partial hydrolysis and decomposition of species 
[RhCp*(L)Z] take place in the basic pH range (see figure 5.a) as it was observed in the case of 
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dhp as well. The pKa of the complex [RhCp*(pic)(H2O)] is higher by more than one order of 
magnitude than that of the analogous Ir(III) complex [26]. In order to exclude the possibility 
of the monodentate coordination of a second ligand via the pyridine nitrogen besides the 
(N,O) binding mode, 1H NMR spectra were recorded at various ligand excess (not shown). 
Peaks being assigned merely to the mono-ligand complex of pic and the free ligand were 
observed and there was no indication for the formation of bis-ligand complexes. 
Figures 4 and 5    
The leaving group Z in the third coordination site of complexes [RhCp*(L)Z] of dhp 
and pic is most probably a water molecule in the absence of chloride ions. However, it can be 
partially (or completely) displaced by a chlorido ligand or the aquation of the chlorido 
complex can undergo after dissolution. Aquation (hydrolysis) is considered as an important 
step of the mechanism of action as in the case of many transition metal anticancer complexes 
[49] such as cisplatin [50] or [Ru(II)(η6-p-cymene)(L)Cl] compounds [51]. The H2O/Cl
- 
exchange process was found to be fast (taking place within ~10 minutes) in the case of the 
RhCp* complexes of pic and dhp. Since the displacement of water by chloride results in 
characteristic spectral changes in the UV-Vis spectra, stepwise stability constants (log 
K’(H2O/Cl
‒) in table 2) could be estimated for the following equilibrium with the 
deconvolution of the spectra (see figure 6 for the dhp complex).  
[RhCp*(L)(H2O)]
+ + Cl− [RhCp*(L)Cl)] + H2O   (2) 
Measurements were performed at pH values where [RhCp*(L)Z] complexes predominate. 
 Figure 6 
Based on the H2O/Cl
‒ exchange constant of the complex [RhCp*(pic)Z] concentration 
distribution curves were calculated at various chloride concentrations (see figure 7). It is 
noteworthy that the equilibrium constant of the pic complex is more than one order of 
magnitude higher than that of dhp or other (O,O) donor ligands [21], which may have effect 
on the bioactivity. With the aid of the K’(H2O/Cl
‒) exchange constants we can estimate the 
ratio of the aqua and the chlorinated complexes at chosen chloride concentrations. E.g. At 100 
mM chloride concentration, which corresponds to the blood plasma, 38% of the dhp and 94% 
of the pic complexes are chlorinated. While at the chloride concentration of the cell nucleus (4 
mM) only 3% and 36% of the complexes of dhp and pic are chlorinated, respectively. 
(Calculations were done at 50 mM concentration of the complexes.) 
Figure 7 
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3.4. Comparison of stability of [RhCp*Z3] and [Ru(II)(h
5-p-cymene)Z3] complexes 
formed with dhp and pic  
 
Our aim in this work was to investigate the differences in the solution speciation of 
[RhCp*Z3] complexes formed with the (O,O) donor 3-hydroxy-4-pyridinone and the (O,N) 
donor picolinate ligand. The complex formation equilibrium, which is characterized by the 
overall stability constant (), is superimposed by other accompanying equilibria such as the 
(de)protonation of the ligand and the hydrolysis of the metal ion. Therefore the overall 
stability constants cannot be compared directly in the case of different ligands and metal ions. 
Derived constants (log K*, in table 2) taken into consideration the different basicities of the 
ligands according to the following competition reaction can be used to compare the stabilities: 
[RhCp*Z3]  + HL  [RhCp*(L)Z] + H
+ + 2 Z   (Z = H2O or Cl
‒) (3) 
The higher derived constants imply more favored complex formation. Log K* values of pic 
are undoubtedly higher than those of dhp and higher chelate stability is found in the absence 
of the competitive chloride ions.     
On the other hand not only the competition of the metal ion with protons for the ligand 
but that of the ligand with the hydroxide for the metal ion has to be taken into consideration, 
which becomes more pronounced at higher and higher pH values. Conditional stability 
constants or pM values can be computed at a fixed pH value or as a function of pH. To 
indicate the difference in the metal binding ability of dhp, pic and maltol for comparison 
towards RhCp* pM values were calculated at various pH values under the same conditions 
(see figure 8). pM values give the negative logarithm of the equilibrium concentrations of the 
non-bound metal ion ([RhCp*Z3] and the μ-hydroxido dinuclear species) under the given 
conditions. Higher pM values indicate stronger chelating ability. The coordination of pic to 
RhCp* starts at more acidic pH values compared with the (O,O) ligands and the RhCp* 
binding ability of the ligands show the following order: maltol < dhp < pic. 
Figure 8 
Overall stability constants of the analogous complexes formed in the Ru(II)(h6-p-
cymene) – dhp / pic / maltol systems are also available in the literature [41,44]. Log  values 
of the Ru(II)(h6-p-cymene) complexes formed with dhp and maltol are higher compared to 
those of RhCp* species, although the picolinate complexes show reverse tendency. The 
hydrolysis constants of compounds Ru(II)(h6-p-cymene) and RhCp* are significantly 
different and this fact has to be taken into consideration when the stabilities are compared. For 
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a more adequate comparison distribution diagrams were computed for these systems at 
physiological pH under identical circumstances with the aid of the overall stability constants 
(see figure 9). Mono-ligand complexes (mainly [MLZ]) predominate at this pH in all cases, 
although their fractions show remarkable differences. The fractions of the metal complexes 
formed with dhp are higher than those of maltol as it was expected since the lesser strength of 
bidentate binding of hydroxypyrones was also found in the case of other metal ions [41,52]. It 
is noteworthy that the metal binding ability of dhp towards Ru(II)(h6-p-cymene) is 
comparable with RhCp* at this particular pH, while complexation of maltol is somewhat 
more favored with RhCp*. On the other hand preference for the (N,O) coordination of pic to 
RhCp* is observed over the binding of the (O,O) donor ligand dhp, although the molar 
fraction of the mono-ligand complexes of dhp is higher in the case of Ru(II)(h6-p-cymene) 
representing some alterations in the binding abilities of these organometallic compounds.  
Figure 9 
 
3.5. Cytotoxicity of RhCp* complexes of dhp and pic 
 
In our previous work, RhCp* complexes formed with hydroxypyrone ligands such as maltol 
and allomaltol were investigated for their anticancer potential in various human cancer cell 
lines [21]. They were found to exhibit minor cytotoxicity, being effective only in a range 
similar to that of the analogous Ru(II)(η6-p-cymene) complexes [53]. Within this work the 
impact of the coordination of the (O,O) donor ligand dhp and the (N,O) donor pic to RhCp* 
on cytotoxicity was investigated by means of the colorimetric MTT assay in the human cancer 
cell lines CH1 (ovarian carcinoma), SW480 (colon carcinoma) and A549 (non-small cell lung 
carcinoma). Cytotoxicity data for the related Ru(II)(h6-p-cymene),  Os(II)(h6-p-cymene) and 
Ir(III)Cp* complexes formed with pic are available in the literature [8,25,26]. The Ru(II)(h6-
p-cymene) complex of pic exhibits IC50 values of 36–82 mM measured against human cancer 
cell lines such as cervix carcinoma and melanoma cells [25].The cytotoxicity of the Os(II)(h6-
p-cymene)-pic complex falls in the range of 17–45 mM tested in lung and ovarian cancer cells 
[8]. However, complex 2 was found to be poorly cytotoxic with IC50 values between ca. 250–
350 mM in the cell lines investigated here. It is noteworthy that the analogous IrCp* complex 
also showed fairly high IC50 values (> 100 mM) [26]. In contrast, the dhp derivative 1 
exhibited moderate activity. CH1 cells were found to be most sensitive followed by SW480 
and A549 cells (see table 3).  
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 Table 3  
Both studied complexes were found to be fairly stable in aqueous solution at pH 7.4. Complex 
2 has somewhat higher stability and possesses higher log K’(H2O/Cl
‒) value compared to 
complex 1, while the cytotoxicity of the latter is roughly 2–5 times higher. Results represent 
no direct relationship between stability and bioactivity, although the stronger affinity towards 
chloride ions at the third coordination position seems to be disadvantageous. The anticancer 
activity is influenced by many other parameters such as the lipophilicity, size and interaction 
with transfer and target macromolecules and these essential binding events are currently 
investigated in our laboratories.  
 
4. Conclusions 
 
The goal of the present study was to characterize and compare the solution speciation of 
RhCp* complexes of ligands dhp and pic together with the investigation of their bioactivity. 
Stoichiometry and stability of the complexes were determined via a combined approach using 
pH-potentiometry, 1H NMR spectroscopy and UV-Vis spectrophotometry in the absence and 
presence of chloride ions. Exclusive formation of the mono-ligand complexes such as 
[RhCp*(L)Z] (L = dhp or pic, Z = H2O or Cl
‒) and [RhCp*(L)(OH)] was detected. Pic forms 
higher stability complexes with RhCp* compared to dhp, although the stability of the 
complexes formed with this ligand significantly exceeds that of hydroxypyrones such as 
maltol. [RhCp*(L)Z] complexes of pic and dhp are predominant at physiological pH even in 
the micromolar concentration range. Partial decomposition of these complexes to the 
biologically inactive dinuclear tri-hydroxido bridged species [(RhCp*)2(μ-OH)3]
+ and to the 
metal-free ligand is expected on the basis of the determined overall stability constants in the 
basic pH range (at pH > ~8‒9 depending on the type of ligand and chloride ion 
concentration). Formation of mixed hydroxido complexes [RhCp*(L)(OH)] was observed and 
could be characterized by relatively high pKa values (9.32‒11.90). Chloride ions act as 
competitive ligands and are able to suppress the formation of RhCp* complexes to some 
extent. Aquation process of [RhCp*(L)Cl] complexes may play an important role in the 
mechanism of action of this type of organometallics, and the extent of the chloride/water 
exchange depends on the chloride concentrations of the biofluid and the exchange constant. 
Therefore, the co-ligand exchange equilibrium for the [RhCp*(L)(H2O)]
+ complexes of dhp 
and pic was studied by UV-Vis spectrophotometry. Based on the constants it can be predicted 
17 
that, e.g., ~38% of the dhp complex exists as the chlorido complex at 0.1 M chloride 
concentration in human blood plasma, whereas the pic complex has a much stronger ability to 
retain the chloride at the third coordination site.  
 In order to investigate the in vitro cytotoxicity of the RhCp* complexes of dhp and 
pic, the compounds were synthesized and characterized. The cytotoxicity of these 
organometallics was studied in the human cancer cell lines (CH1, SW480 and A549). The pic 
complex showed no relevant cytotoxicity, whereas the organorhodium dhp analogue exhibited 
moderate cytotoxicity depending on the cell line. Thus, the dhp complex was found to be 
significantly more active than the pic derivative, although the latter is more stable in aqueous 
solution and has higher H2O/Cl
‒ exchange constant for the species [RhCp*(L)Z]. These 
results confirm that the cytotoxicity depends on the attached ligand scaffold, and the bioactive 
ligand scaffold dhp seems to be beneficial with regard to the anticancer potential.  
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Chart 1. Chemical structures of dhp (a), pic (b) in their neutral forms and [RhCp*(H2O)3]
2+ (c). 
 
 
 
 
Chart 2. Chemical structures of RhCp* complexes of dhp (1) and pic (2). 
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 Figure 1. Solid state structure of complex 
molecules are omitted for clarity.
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1 drawn at 50% probability level. Hydrogens and solvent 
 
23 
  
Figure 2. Representative 1H NMR spectra of the [RhCp*Z3] – dhp system in chloride-containing 
aqueous solution recorded at various pH values showing the regions of the chemical shifts of the 
methyl protons: N-CH3 of dhp (a), C
2CH3 of dhp (b) and CH3 of Cp* (c). Symbols: ×: [RhCp*(dhp)Z], 
■: free ligand (in different protonation states), ●: [RhCp*Z3], ∆: [(RhCp*)2(μ-OH)3]
+. {cM = cL = 1 
mM; T = 25 ˚C; I = 0.20 M (KCl); 10% D2O; Z = H2O or Cl
-}. 
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Figure 3. Concentration distribution curves of the [RhCp*Z3] – dhp system calculated with the aid of 
the overall stability constants (solid lines). Molar fractions based on the 1H NMR peak integrals of the 
methyl protons of Cp*. ×: [RhCp*(dhp)Z] and [RhCp*(dhp)(OH)] together; ●: [RhCp*Z3]; ∆: 
[(RhCp*)2(μ-OH)3]
+. {cM = cL = 1 mM; T = 25 ˚C; I = 0.20 M (KCl); 10% D2O; Z = H2O or Cl
-}.  
 
 
 
Figure 4. Representative 1H NMR spectra of the [RhCp*Z3] – pic system in chloride-containing 
aqueous solution recorded at various pH values showing the regions of the chemical shifts of the 
methyl protons of Cp*. Symbols: ×: [RhCp*(pic)Z]; ●: [RhCp*Z3]; ∆: [(RhCp*)2(μ-OH)3]
+. {cM = cL = 
1 mM; T = 25 ˚C; I = 0.20 M (KCl); 10% D2O; Z = H2O or Cl
-}. 
  
0.0
0.2
0.4
0.6
0.8
1.0
2 4 6 8 10
m
o
la
r 
fr
a
c
ti
o
n
o
f 
R
h
C
p
*
pH
[RhCp*Z3]
[RhCp*(dhp)Z]
[(RhCp*)2(m-OH)3]
+
[RhCp*(dhp)(OH)]
([RhCp*(dhp)Z] +
[RhCp*(dhp)(OH)])
pH
11.45
11.05
10.73
10.22
9.73
9.19
8.73
8.29
7.15
4.14
2.91
2.42
1.92
[RhIII(Cp*)(L)Z] → [RhIII(Cp*)(L)(OH)]
× ●
∆
1.72     1.68    1.64    1.60    1.56
d / ppm
[Rh p*(L)Z]  [ hCp*(L)( )]C pic)Z] → [RhCp*(pic)(OH)]
25 
 
 
Figure 5. Concentration distribution curves of the [RhCp*Z3] – pic (1:1) system in chloride-free 
(dotted lines) and chloride-containing (solid lines) aqueous solutions as a function of pH (a). Molar 
fractions of complex [RhCp*(pic)Z] plotted against analytical (total) complex concentrations at pH 
7.40 in chloride-free (dotted lines) and chloride-containing (solid lines) solutions (b). {cM = cL = 1 mM 
(a); T = 25 ˚C; I = 0.20 M (KCl or KNO3); Z = H2O or Cl
‒}.  
 
 
 
Figure 6. UV–Vis spectra recorded for the water/chloride exchange process in the complex 
[RhCp*(dhp)(H2O)]
+ at physiological pH. Inset shows the individual calculated spectra of complexes 
[RhCp*(dhp)(H2O)]
+ and [RhCp*(dhp)Cl]. {cM = cL = 0.27 mM; cKCl = 0‒1.0 M; T = 25 ˚C; pH = 
7.40)}. 
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Figure 7. Absorbance values measured for the complex [RhCp*(pic)(H2O)]
+ at 308 nm (■) at various 
chloride ion concentrations and calculated concentration distribution curves (solid lines) calculated 
with the aid of the formation constant log K’ (H2O/Cl
‒) for the water/chloride exchange process. {cM = 
cL = 0.27 mM; cKCl = 0‒51 mM; T = 25 ˚C; pH = 3.50}. 
 
 
 
 
Figure 8. pH-dependence of pM values calculated for the [RhCp*Z3] – pic / dhp / maltol systems 
under identical conditions. pM = –log[M]; where [M] is the equilibrium concentration of the ligand-
free, non-bound metal ions. {cM = 1 mM; M:L = 1:1; T = 25 ˚C; I = 0.20 M (KCl; Z = H2O or Cl
‒)} 
Calculation for the maltol-containing system is based on data from Ref. [21]. 
 
0.29
0.34
0.39
0.44
0.0
0.2
0.4
0.6
0.8
1.0
0 10 20 30 40 50 60
A
b
s
o
rb
a
n
c
e
 a
t 3
0
8
 n
m
m
o
la
r 
fr
a
c
ti
o
n
o
f 
R
h
C
p
*
cKCl / mM
[RhCp*(pic)Cl]
[RhCp*(pic)(H2O)]
+
3.0
4.0
5.0
6.0
2 4 6 8 10
p
M
pH
pic
dhp
maltol
27 
 
Figure 9. Concentration distribution diagrams of complexes formed in the [RhCp*Z3] / [Ru(II)(h
6-p-
cymene)Z3] – dhp / pic / maltol systems calculated at physiological pH with the aid of the overall 
stability constants. {cM = cL = 100 mM; pH = 7.40; T = 25 ˚C; I = 0.20 M (KCl; M = RhCp* or 
Ru(II)(h6-p-cymene); Z = H2O or Cl
‒)} Calculations for the [RhCp*Z3] – maltol and [Ru(II)(h
6-p-
cymene)Z3] containing systems are based on data from Refs. [21,41]. 
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Table 1 
Crystal data and details of data collection for the RhCp* complex of dhp (1) 
Compound 1 
Empirical formula      C20H23ClNO2Rh∙3CHCl3 
Formula weight / g/mol 769.83 
Temperature / K 100(0) 
Wavelength /  0.71073 
Crystal size / mm 0.12 × 0.15 × 0.30  
Crystal system  monoclinic 
space group        P21/n 
a / Å 16.1522(10) 
b / Å 9.5797(6) 
c / Å 20.1702(16) 
 / ° 90.00 
β/ ° 108.2910(19) 
γ / ° 90.00 
Volume / Å3 2963.3(3) 
Z 4 
Calculated density / mg/m3 1.726 
Absorption coefficient / mm-1 1.498  
F(000)          1536 
 range for data collection    1.94–25.39° 
Index ranges           -19 ≤ h ≤ 19 
-11≤ k ≤ 11 
-24 ≤ l ≤ 24 
Reflections collected / unique     87951 / 5445 
Data / restraints / parameters     5445 / 0 / 314 
R(int) 0.0277 
Goodness-of-fit on F2 a 1.051 
Final R indices [I>2σ(I)] b  
R1 0.0182 
wR2 0.0449 
a GOF = {[w(Fo
2 – Fc
2)2] /(n – p)}1/2, where n is the number of reflections 
and p is the total number of parameters refined. 
b R1 = Fo - Fc/Fo. wR2 = {[w(Fo
2 – Fc
2)2]/[w(Fo
2)2]}1/2 
Table 2 
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Proton dissociation constants (pKa) of dhp and pic and overall stability constants (log ) of 
their RhCp* complexes in chloride-containing and chloride-free solutions determined by pH-
potentiometry {T = 25 C; I = 0.20 M}.a 
 dhp pic 
 0.20 M KCl 0.20 M KNO3 0.20 M KCl 0.20 M KNO3 
pK1 (ligand) 3.64 ± 0.01 3.67 ± 0.01 5.26 ± 0.01 5.21 ± 0.01 
pK2 (ligand) 9.77 ± 0.01 9.66 ± 0.01 ‒ ‒ 
log [MLZ]b 8.93 ± 0.01 10.90 ± 0.01 8.90 ± 0.01c 9.18 ± 0.01c 
log [MLH‒1]
d ‒2.97 ± 0.07 0.23 ± 0.03 ‒1.54 ± 0.02 ‒0.14 ± 0.02 
pK [MLZ] 11.90 10.67 10.44 9.32 
log K* e ‒0.84 +1.24 +3.64 +3.97 
log K’ (H2O/Cl
‒) f 0.78 ± 0.01 2.20 ± 0.01 
a Charges are omitted for simplicity. M denotes RhCp*. Hydrolysis products of the organometallic 
fragment: log [M2H‒2] = ‒11.12, log [M2H‒3] = ‒19.01 at I = 0.20 M (KCl) and log [M2H‒2] = 
‒8.53, log [M2H‒3] = ‒14.26 at I = 0.20 M (KNO3) taken from Ref. [21]. 
b Z = H2O or Cl
‒ for 
chloride-containing samples; Z = H2O for chloride-free media. 
c Determined by UV-Vis 
spectrophotometry at pH 0.7-2. d As H+ is defined as a component, H−1 indicates the deprotonation of a 
coordinated H2O molecule, or coordination of OH
−. e log K* = log  [MLZ] − pK (HL). f For the 
[RhCp*(L)(H2O)]
+ + Cl−  [RhCp*(L)Cl] + H2O equilibrium determined at various total chloride 
concentrations by UV-Vis. 
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Table 3  
In vitro cytotoxicity (IC50 values in µM) of the RhCp* complexes of dhp (1), pic (2) and 
maltol for comparisona 
 
   
Cell line 
1 2 
 maltolato 
complexb 
CH1 50 ± 2 258 ± 6 120 ± 16 
SW480 112 ± 15 283 ± 65 178 ± 26 
A549 165 ± 14 343 ± 24   306 ± 34 
a 96 h exposure, b Data taken from Ref. [21]  
 
 
